TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.
about
Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and TargetsElimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cellsImproved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells.Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndromeMalignant inflammation in cutaneous T-cell lymphoma-a hostile takeoverNFκB function and regulation in cutaneous T-cell lymphoma.Novel therapies for cutaneous T-cell lymphoma: what does the future hold?Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.Sézary syndrome: old enigmas, new targets.Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control study.STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment.A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.Genomic landscape of cutaneous T cell lymphoma.Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.Th1 epitope selection for clinically effective cancer vaccines.Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
P2860
Q26746551-C149387A-83E1-48A2-A485-64134FFBEFB8Q33679779-4668D0D0-7E14-48AD-8C7F-9BE1C92FCF28Q33987080-A1424199-33A0-4B8B-ACC9-E36B924EAC16Q34516083-E5C3BD57-6438-4939-99F0-169DFF698F58Q35129052-1AF5510B-4933-437D-8B8B-CD9977C4FFBFQ35572112-2F3B61BB-BDA2-428B-BC3E-88513935EC4BQ35584244-4A00A33F-3326-4B3A-906E-1178E9E47044Q35586076-73731C7B-977F-472B-8481-3EB79A5AB5C5Q37139517-3DEB491D-36EA-44AF-915C-72DBE0D16164Q37688819-D8BB319C-AD0C-4A29-BBE1-8443E8631C98Q37723390-94CF23AF-CA85-4CFB-8B13-5490E315ED03Q38162229-F7317690-3994-4460-9892-4821841E4FE0Q38176398-0E099430-DF95-4C2D-B243-FF303C107BB6Q38677720-A98B5BD5-B281-434B-A45F-605C98043254Q38757938-2F44BEAD-D909-4037-A3B8-0D06DF63FEA9Q38772711-98508FDA-37AE-4B97-89E1-B09516AD1E60Q39038768-865CB2F9-5CE6-4522-9887-4597AD85AD69Q40527083-D8C0EE72-93C5-49F0-AE15-F35CB321ABEDQ40545134-3F0D2381-CFB6-473E-B751-3DAFBC76D141Q40802496-A540EF75-98AF-47A3-9396-5B059E29C422Q41139626-4EDEE812-5D1A-498D-98CD-3594F3D812E8Q41940144-F702EF67-C7A4-4253-9D3C-586E46D927E6Q42004035-A0518602-3312-423E-9741-95A1384F145EQ42027899-638E4DEF-8293-4E73-9AE2-B05773BCD390Q42503675-0631F8F8-F629-43F3-A2A8-E366C83C243CQ42553514-23500EA1-FAF8-4264-B39E-89345EA49F02Q46248185-FD585BA2-CB49-4BA1-B0B3-7ED0251C116DQ49710218-9DAAC25E-79A2-4675-A7B8-E0471D304517Q55334211-454CE6E6-5DDD-4A52-82DE-A9E11EB7AAB3
P2860
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@en
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@nl
type
label
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@en
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@nl
prefLabel
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@en
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@nl
P2093
P2860
P1476
TH2 cytokines from malignant c ...... mic cutaneous T-cell lymphoma.
@en
P2093
Alain H Rook
Christoph Schlapbach
David C Fisher
Emmanuella Guenova
Jennifer A Desimone
Jessica E Teague
Knut Schaekel
Marianne Tawa
Mitra Dowlatshahi
Rachael A Clark
P2860
P304
P356
10.1158/1078-0432.CCR-12-3488
P407
P577
2013-06-19T00:00:00Z